Evidence map›Paper›PMID 41126740›Full record

ReviewCNS spectrums2025

Melatonin dose and timing: Do we have it right?

Shobha George, Anushree Sripathy, Aysha Rehman, Joseph George, Kanishk Chirayil, Emma Frost, Nalini Ramanathan, Simy Joseph, Karim Ghobrial-Sedky, Akshay Sripathy and 3 more

Abstract readReview
In one paragraph

Review in CNS spectrums, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shobha GeorgeCollege of Arts and Sciences, https://ror.org/01sbq1a82University of Delaware, Newark, DE, USA.ORCID 0009-0007-7953-5516
Anushree Sripathyhttps://ror.org/05qghxh33Stony Brook University, Stony Brook, NY, USA.
Aysha RehmanDepartments of Psychiatry and Human Behavior and Child and Adolescent Psychiatry, https://ror.org/01z7r7q48The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Joseph GeorgeSchool for Science and Mathematics, South Carolina Governor'sHartsville, SC, USA.
Kanishk ChirayilStone Bridge High School, Ashburn, VA, USA.
Emma Frosthttps://ror.org/049wjac82Cooper Neurological Institute, Cooper University Health Care, Camden, NJ, USA.
Nalini RamanathanFamily Medical Group, St Peter's Health Partners, Albany, NY, USA.
Simy JosephDepartment of Medicine, Teamhealth Inc, Knoxville, TN, USA.
Karim Ghobrial-SedkyDepartment of Psychiatry, https://ror.org/022e9hp02Family Health Centers of San Diego, San Diego, CA, USA.
Akshay SripathyGuilderland High School, Hamlet, NY, USA.
Jose MaldonadoDepartment of Psychiatry and Behavioral Sciences, https://ror.org/03mtd9a03Stanford University School of Medicine, Stanford, CA, USA.
Jeff McCaghSheppard Pratt Health System, Baltimore, MD, USA.
Maju Mathew KoolaDepartment of Psychiatry and Behavioral Sciences, https://ror.org/049wjac82George Washington University, Washington, DC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melatonin is an easily accessible, widely used drug for sleep issues, disrupted sleep-wake cycles, and jet lag, available in a variety of forms and dosages. Melatonin is also used in hospital settings to promote sleep onset, particularly in elderly patients, as a circadian rhythm regulator. Despite the popularity of melatonin, it is not approved by the US Food and Drug Administration (FDA). This creates ambiguity surrounding its proper usage for optimum results, including dosage and time of administration. The objective of this article is to shed light on the best timing to administer melatonin. Melatonin is a hormone that our body naturally produces to regulate our biological clock. Even though our body has a built-in "sleep system," many people still suffer from chronic sleep disorders such as insomnia. Melatonin has also proved to help prevent delirium in hospitalized patients due to its circadian rhythm regulatory effects. The elderly are at risk of developing insomnia because as one ages, melatonin production decreases. The most convenient solution for insomnia is to take melatonin supplements. To optimize the effects of melatonin supplements, proper dosage and timing must be considered. Additionally, patients who are oppositional to bedtime, which is known as bedtime resistance, are typically more willing to go to bed following melatonin administration. Melatonin administration at around 6 PM (1-2 hours before bedtime) is optimal to regulate sleep cycles of patients, and it can help with bedtime resistance. This should be the standard of care in all hospitals, nursing homes, and at home.

Indexed as

MelatoninSleep Initiation and Maintenance DisordersCircadian RhythmHumansSleepMelatonincircadian rhythmdeliriuminsomniamelatoninramelteon

Identifiers

PMID41126740
PMCPMC13064696

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.